A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

被引：0
作者：
Dizman, Nazli
Adra, Nabil
Vaishampayan, Ulka N.
Xiao, Lianchun
Yuan, Ying
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Tannir, Nizar M.
Shah, Amishi Yogesh
Msaouel, Pavlos
Hahn, Andrew Warren
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[3] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4542
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, Chung-Han
    Shah, Amishi Y.
    Makker, Vicky
    Taylor, Matthew
    Shaffer, David
    Hseih, James J.
    Cohn, Allen L.
    Di Simone, Chris
    Marin, Alvaro Pinto
    Rasco, Drew
    Gunnestad-Ribe, Sara
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Perini, Rodolfo
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 101 - 102
  • [32] A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy
    Msaouel, Pavlos
    Thall, Peter F.
    Yuan, Ying
    Wang, Xuemei
    Jonasch, Eric
    Gao, Jianjun
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Corn, Paul Gettys
    Tam, Alda
    Ahrar, Kamran
    Rao, Priya
    Sircar, Kanishka
    Der-Torossian, Hirak
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.
    Ciccarese, Chiara
    Iacovelli, Roberto
    Bria, Emilio
    Schinzari, Giovanni
    Rossi, Ernesto
    Astore, Serena
    Cannella, Maria Antonella
    D'Angelo, Tatiana
    Cicala, Carlo Maria
    Maratta, Maria Grazia
    Tortora, Giampaolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naive metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
    George, Saby
    Herbst, Laurie
    Sikorski, Marcus
    Diraddo, Ann Marie
    Azabdaftari, Gissou
    Roche, Charles
    Kauffman, Eric
    Li, Qiang
    Schwaab, Thomas
    Levine, Ellis Glenn
    Pili, Roberto
    Chatta, Gurkamal S.
    Appleman, Leonard Joseph
    Groman, Adrienne
    Parikh, Rahul Atul
    Hutson, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [35] Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma
    Reimers, Melissa A.
    Figenshau, Robert S.
    Kim, Eric H.
    Tucker, Julie
    Kasten, Nicole
    Khan, Adeel S.
    Hanneken, Jan M.
    Smith, Zachary L.
    Hsieh, James J.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (05) : 361 - 366
  • [36] Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma
    Tai, Warren
    Doolittle, Gary C.
    Shah, Zubair
    Atkinson, James B.
    Russell, Elaine
    Genton, Randall E.
    Moslehi, Javid J.
    Porter, Charles B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (12) : 1860 - 1864
  • [37] Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
    Gedye, C.
    Harris, C. A.
    Stockler, M. R.
    Morris, M.
    Ferguson, T.
    Goh, J. C. H.
    Martin, A.
    Underhill, C. R.
    Pook, D.
    Krieger, L. E. M.
    Kichenadasse, G.
    Joshi, A. J.
    Subramaniam, S.
    Zebic, D. S.
    Zhang, A.
    Joshua, A. M.
    Toner, G. C.
    Vasey, P. A.
    Prithviraj, P.
    Davis, I. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1014 - S1014
  • [38] Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies
    Nathani, Kaizen
    Touma, Amina
    Elias, Roy
    Pallauf, Maximilian
    Markowski, Mark Christopher
    Carducci, Michael Anthony
    Singla, Nirmish
    Ged, Yasser
    Ged, Yasser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 446 - 446
  • [39] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean T.
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [40] RACIAL DIFFERENCES IN OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS MANAGED ON IMMUNE-CHECKPOINT INHIBITOR (ICI) THERAPY
    Olsen, T. Anders
    Martini, Dylan
    Goyal, Subir
    Liu, Yuan
    Evans, Sean
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Master, Viraj
    Kucuk, Omer
    Carthon, Bradley
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A133 - A133
12345